Aptinyx Inc (NASDAQ: APTX) is pleased to unveil some of the most important details regarding the Mid-Stage NYX-783 Program In PTSD Patients.
Focusing on the NYX-783
A lot has been happening; lately, one of the most important moves being the Type C meeting the company held with the FDA. In addition, Aptinyx Inc has completed the designing of its Phase 2b program for NYX-783. Finally, the company sought to provide some working solutions to all the patients struggling with post-traumatic stress disorder.
Everything has been planned in a rather elaborate way, according to a company official. The latest program focuses on NYX-783, in which case the studies embark on observing the two dose levels. Those include 50 mg (Study 1) and 150 mg (Study 2).
The company speaks out about the two studies, outlining that they will consist of about 300 patients.
The scheduling of the studies happens to be the other thing, with the company mentioning Q4 of 2021 as the particular moment that Study 1 swings into effect. Then, in Q1 of 2022, Study 2 will commence according to a statement from the leading company.
Aptinyx speaks out about the recently concluded exploratory Phase 2 study in PTSD, presenting the updated statistical analysis rather elaborately. One important point that comes to light is that the company’s contract research organization committed a statistical error.
The CEO of the company Norbert Riedel opines, “The revised analysis does not impact our conclusions from that study, our confidence in the efficacy and safety profile of NYX-783, or our next steps in its clinical development.”
The updated statistical analysis presents particular study calculations such as the CAPS-5 Negative Cognitions and the CAPS-5 Arousal & Reactivity score.